02 November 2023
Volume 5 · Issue 11


In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of tweets. This month she is talking about #domperidone

Day 1: After recognition that early antipsychotic drugs acting on dopamine pathways had an impact on vomiting, the search was on for an anti-emetic without extra pyramidal side-effects (EPS). #domperidone was licensed in the 1970s

Day 2: Indications for #domperidone; relief of nausea/vomiting for those over 12 years & over 35kg. Dose 10mg up to three times/day for 1 week, including 2nd line for nausea/vomiting in pregnancy. Same dose used for GI pain in adult palliative care

Day 3: #domperidone has rapid oral absorption with high first pass metabolism in the gut & liver. High Vd (low concn in brain), hepatic phase 1 breakdown e.g CYP3A4 & 1A2. 2/3 faecal excretion with small amount unchanged. T½ 7-9hrs; prolonged if severe renal or hepatic impairment

Day 4: #domperidone has a dual anti-emetic effect via blocking dopamine receptors in the chemoreceptor trigger zone & accelerating gastric motility & emptying (pro-kinetic effect)

Day 5: Common ADEs: dry mouth. Uncommon: reduced libido, anxiety, headache, diarrhoea, breast pain. Unknown: anaphylactic reaction, convulsion, urinary retention, ventricular arrhythmia, sudden cardiac death, QT prolongation, Torsade de Pointes (NOT exhaustive)

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month